PIERIS PHARMACEUTICALS INC's ticker is PIRS and the CUSIP is 720795103. A total of 50 filers reported holding PIERIS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $141,620 | +2.2% | 772,784 | +1.5% | 0.00% | – |
Q4 2023 | $138,625 | -38.9% | 761,444 | 0.0% | 0.00% | – |
Q3 2023 | $226,987 | +106.7% | 761,444 | +14.8% | 0.00% | – |
Q2 2023 | $109,800 | -82.1% | 663,449 | +5.3% | 0.00% | – |
Q1 2023 | $614,845 | +93769.5% | 629,965 | 0.0% | 0.00% | – |
Q4 2022 | $655 | -99.9% | 629,965 | -0.2% | 0.00% | – |
Q3 2022 | $726,000 | -38.4% | 631,454 | +0.2% | 0.00% | – |
Q2 2022 | $1,178,000 | -33.7% | 630,478 | +7.5% | 0.00% | – |
Q1 2022 | $1,776,000 | -27.6% | 586,315 | -9.6% | 0.00% | – |
Q4 2021 | $2,452,000 | -31.6% | 648,721 | -6.5% | 0.00% | – |
Q3 2021 | $3,586,000 | +63.6% | 693,696 | +21.2% | 0.00% | – |
Q2 2021 | $2,192,000 | -0.5% | 572,387 | -33.3% | 0.00% | – |
Q1 2021 | $2,204,000 | +3.3% | 857,940 | +0.6% | 0.00% | – |
Q4 2020 | $2,133,000 | +26.7% | 853,230 | +4.9% | 0.00% | – |
Q3 2020 | $1,683,000 | -26.8% | 813,250 | +9.6% | 0.00% | – |
Q2 2020 | $2,300,000 | +40.7% | 742,026 | +3.5% | 0.00% | – |
Q1 2020 | $1,635,000 | -63.9% | 717,210 | -42.7% | 0.00% | – |
Q4 2019 | $4,528,000 | +113.9% | 1,251,788 | +101.6% | 0.00% | – |
Q3 2019 | $2,117,000 | +69.0% | 620,846 | +132.9% | 0.00% | – |
Q2 2019 | $1,253,000 | +51.0% | 266,611 | +7.5% | 0.00% | – |
Q1 2019 | $830,000 | -46.1% | 247,969 | -57.2% | 0.00% | – |
Q4 2018 | $1,540,000 | -8.3% | 579,548 | +93.2% | 0.00% | – |
Q3 2018 | $1,679,000 | +15.4% | 299,995 | +4.5% | 0.00% | – |
Q2 2018 | $1,455,000 | -15.7% | 287,165 | +13.5% | 0.00% | -100.0% |
Q1 2018 | $1,725,000 | +14.3% | 253,088 | +26.6% | 0.00% | 0.0% |
Q4 2017 | $1,509,000 | +162.9% | 199,945 | +100.5% | 0.00% | – |
Q3 2017 | $574,000 | +42.1% | 99,738 | +24.7% | 0.00% | – |
Q2 2017 | $404,000 | +494.1% | 79,953 | +204.7% | 0.00% | – |
Q1 2017 | $68,000 | +277.8% | 26,244 | +103.9% | 0.00% | – |
Q4 2016 | $18,000 | -21.7% | 12,868 | 0.0% | 0.00% | – |
Q3 2016 | $23,000 | +15.0% | 12,868 | 0.0% | 0.00% | – |
Q2 2016 | $20,000 | -16.7% | 12,868 | 0.0% | 0.00% | – |
Q1 2016 | $24,000 | -17.2% | 12,868 | 0.0% | 0.00% | – |
Q4 2015 | $29,000 | +26.1% | 12,868 | 0.0% | 0.00% | – |
Q3 2015 | $23,000 | – | 12,868 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 1,360,000 | $6,895,000 | 5.06% |
Omega Fund Management, LLC | 778,230 | $3,946,000 | 2.91% |
BVF INC/IL | 5,346,838 | $27,108,000 | 2.65% |
Virtus ETF Advisers LLC | 152,550 | $773,000 | 0.68% |
SPHERA FUNDS MANAGEMENT LTD. | 842,632 | $4,272,000 | 0.59% |
Tekla Capital Management LLC | 2,087,380 | $10,583,000 | 0.40% |
Schonfeld Strategic Advisors LLC | 828,600 | $4,201,000 | 0.23% |
Orbimed Advisors | 3,140,000 | $15,920,000 | 0.19% |
Lombard Odier Asset Management (USA) Corp | 563,878 | $2,859,000 | 0.19% |
Rhenman & Partners Asset Management AB | 300,000 | $1,521,000 | 0.16% |